Additionally, anti-CD133 antibody-modified SN-38 nanoparticles can selectively act on CD133-positive CRC stem cells, inhibiting their proliferation and inducing apoptosis, thus providing new possibilities for targeted therapy of CRC (36). Here, PROM1 is linked to colorectal carcinoma.